-
Reading Cell Death with AO/PI: From Signal to Strategy
2026-09-09
A mechanistic and translational guide to using the AO/PI Double Staining Kit for distinguishing viable, apoptotic, and necrotic cells. The article connects Acridine Orange Propidium Iodide staining with melanoma treatment research, explains how to validate fluorescence phenotypes with orthogonal assays, and outlines practical strategies for making cell-death data more decision-ready.
-
Beyond Tagging: 3X FLAG for Translational Rigor
2026-09-09
Mechanistic studies of NINJ1-mediated membrane rupture illustrate why translational researchers need more than a detectable tag: they need orthogonal evidence, controlled workflows, and clear limits on interpretation. This article positions the 3X (DYKDDDDK) Peptide as a practical tool for recombinant protein purification, detection, structural studies, and assay standardization.
-
PPZ1–TORC1 Ferroptosis in Candida albicans
2026-09-09
The reference study identifies a PPZ1–TORC1 regulatory axis that controls tert-butyl hydroperoxide-induced ferroptosis and antifungal resistance in Candida albicans. Its findings connect fungal-specific phosphatase signaling, autophagy, iron-dependent lipid peroxidation, and drug susceptibility, providing a mechanistic basis for ferroptosis-oriented antifungal strategies.
-
Clozapine N-oxide (CNO) for Circuit Research
2026-09-08
Clozapine N-oxide (CNO) enables non-invasive DREADD-based neuronal activity modulation, from acute circuit tests to multi-day cardiovascular phenotyping. This practical guide connects formulation, controls, sympathetic physiology, imaging, and troubleshooting so researchers can build more reproducible chemogenetic workflows.
-
MMP7 Drives Liver Fibrosis in Biliary Atresia
2026-09-07
The 2026 study by Rong and colleagues identifies MMP7 as a mechanistic driver of biliary atresia-associated liver fibrosis, linking E-cadherin cleavage to β-catenin nuclear translocation and epithelial–mesenchymal transition. Its combination of patient samples, transcriptomic analysis, biliary epithelial cell experiments, and chronic disease modeling provides a framework for evaluating MMP7 blockade as an anti-fibrotic strategy.
-
Dihydroartemisinin: Applied Research Workflows
2026-09-07
Build reproducible malaria, mTOR, inflammatory, and cell-proliferation assays around a light-sensitive artemisinin derivative. This guide combines solvent handling, reference-informed parasite workflows, orthogonal controls, and practical troubleshooting without overstating evidence from related compounds.
-
Epigenetic Plasticity in Metastatic HNSCC
2026-09-05
Feng and colleagues integrate single-cell, trajectory, genetic, structural, epigenomic, functional, and clinical evidence to identify WDR54 as a regulator of cellular identity reshaping in metastatic head and neck squamous cell carcinoma. The study links WDR54 to TGF-β-associated partial epithelial–mesenchymal transition, CAF-like conversion, invasion, and immune evasion, while also defining practical considerations for spatial validation of the reported cell states.
-
GLP-1R Cross-Talk Revealed by FRET cAMP Assays
2026-09-04
Chepurny and colleagues used high-throughput FRET measurements of cAMP, pharmacological antagonism, molecular modeling, and cell-based validation to show that glucagon can activate the GLP-1 receptor in addition to its canonical glucagon receptor. The findings clarify how ligand cross-reactivity can affect metabolic experiments and support more rigorous receptor-attribution strategies for type 2 diabetes research.
-
Letrozole A1307 for Reliable Cell Assays
2026-09-04
Learn how Letrozole (SKU A1307) can help researchers design more interpretable viability, proliferation, and cytotoxicity assays through mechanism-aware dosing and disciplined DMSO handling. The guide connects biochemical potency, estrogen receptor readouts, storage, and vendor-selection criteria to practical laboratory decisions.
-
Ziprasidone, GOT1, and PDAC Metabolic Reprogramming
2026-09-03
The reference study identifies ziprasidone as a non-competitive inhibitor of GOT1, linking direct enzyme inhibition with glutamine-metabolism disruption, redox imbalance, and reduced pancreatic ductal adenocarcinoma growth. Its combination of biochemical, cellular, metabolic, genetic, and xenograft evidence provides a useful framework for evaluating GOT1 as a therapeutic vulnerability while leaving questions about selectivity and clinical translation unresolved.
-
EZ Cap™ Human PTEN mRNA (ψUTP) Workflow
2026-09-03
Build more controlled PTEN restoration assays with Cap 1, pseudouridine-modified, polyadenylated mRNA. This practical guide connects delivery design, pathway-level validation, and troubleshooting for cancer research models, including trastuzumab-resistant breast cancer systems.
-
AZD1390: A Decision Framework for ATM–G4 Stress
2026-09-02
AZD1390 is a selective ATM kinase inhibitor for separating radiation-driven DNA damage from replication-associated G-quadruplex stress. This article translates REV1–DHX36 findings into practical assay decisions for cancer research, with emphasis on glioblastoma radiosensitization and mechanistic controls.
-
SU6656: A Src Inhibitor for Polyploidization
2026-09-02
Explore how SU6656, a Src tyrosine kinases inhibitor, can be evaluated in megakaryocyte polyploidization assays and preclinical cancer research. This guide distinguishes validated findings from protocol-level hypotheses and connects assay design with radiotherapy studies.
-
Cell Counting Kit-8 for MgO Implant Studies
2026-09-01
Use Cell Counting Kit-8 to quantify how MgO coating chemistry and gamma-ray treatment affect bone-forming cell survival and expansion. This workflow separates true cytotoxicity from material interference while pairing metabolic readouts with osteogenic and antibacterial endpoints.
-
KPT330 and Cas9 Precision via mRNA Export
2026-09-01
The reference study identified selective inhibitors of nuclear export, including KPT330, as indirect modulators that improve CRISPR-Cas9 and base-editing specificity by interfering with Cas9 mRNA export rather than directly blocking Cas9 protein. Its findings establish transcript trafficking as a controllable layer for genome-editing safety, while also highlighting the need to validate compound effects across editors, cell types, and delivery formats.